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Abstract 
Providing best clinical care involves using the best available evidence of effectiveness 
to inform treatment decisions. Producing this evidence begins with trials and 
continues through synthesis of their findings towards evidence incorporation within 
comprehensible, usable guidelines, for clinicians and patients at the point of care. 
However, there is enormous wastage in this evidence production process, with less 
than 50% of the published biomedical literature considered sufficient in conduct and 
reporting to be fit for purpose. 
Over the last 30 years, independent collaborative initiatives have evolved to optimize 
the evidence to improve patient care. These collaborations each recommend how to 
improve research quality in a small way at many different stages of the evidence 
production and distillation process. When we consider these minimal improvements  
at each stage from an ‘aggregation of marginal gains’ perspective, the accumulation 
of small enhancements aggregates, greatly improving the final product of ‘best 
available evidence’. 
The myriad of tools to reduce research quality leakage and evidence loss should be 
routinely used by all those with responsibility for ensuring that research benefits 
patients, i.e. those who pay for research (funders), produce it (researchers), take part 
in it (patients/ participants) and use it (clinicians, policy makers and service 
commissioners). 
200 words  
  
What is Evidence Based Dentistry Anyway? 
The best known and most widely accepted definition of evidence-based practice was 
suggested by David Sackett back in the 1990s; “Evidence-based medicine is the 
integration of best research evidence with clinical expertise and patient values”1 (see 
Fig 1). 
Improving our standard of deliverable patient care requires maximisation of each of 
these three domains. This article focuses on the ‘best evidence’ domain. 
What is the pathway of evidence production? 
Oral and dental research shares the same goals as the rest of healthcare research; to 
benefit people and patients, whether at an individual or a societal level. Clinical trials 
form the backbone of our clinical evidence in relation to the effect of interventions. 
Trials investigate a new intervention (or an old one applied in a new way) with 
standard treatment, or they compare two or more standard preventive strategies or 
treatments. These comparisons allow us to work out which strategy or treatment has 
the best outcome that we are interested in for a particular condition.  
Although evidence is produced for action, findings from a single study (primary 
research) are no longer enough to call for a change in practice. Figure 2 shows a 
simplified ideal pathway for synthesis of primary research studies into understandable 
and implementable evidence. In reality this is more complex: there are stages before 
clinical trials, for example, investigations of new drugs in laboratories. Also, 
information actually feeds both ways in the process, with findings from trials being 
incorporated back into earlier stages to refine and improve interventions  in future 
trials. Finally, not all interventions or preventive strategies can be tested in controlled 
trials – some can only be assessed through other types of research such as 
observational trials. Examples of these include linking smoking with lung cancer and 
using public health research to evaluate the introduction of healthy public policies. 
However, for the purposes of this paper, it is sufficient to consider controlled clinical 
trials and the pathway in Figure 2. 
Clinical Trials 
Well-designed and conducted trials will provide information to fill a gap or strengthen 
the evidence base. By using the same outcomes and outcome measures as other trials 
in the same area, the information can be assimilated with them.  Complete and 
transparent reporting of the trial protocol and the trial itself (including descriptions of 
participants, settings, and interventions) gives context to the trial. This helps the 
findings and their relevance to be well understood by those reading it.  This clarity is 
also essential to allow systematic reviewers to extract relevant data.  
Systematic Reviews 
Systematic reviews (secondary research) compile and/or pool data from several trials 
looking at the same thing. The strengths of reviews lie in the richness of information 
generated through combining and contrasting research data from different 
researchers, involving diverse groups of participants and carried out in often dissimilar 
circumstances. All pertinent trials are identified and outcomes relevant to 
stakeholders analysed. Again, clear and thorough reporting of methodology, quality 
and bias in the incorporated trials is essential for interpretation of the results. 
Guidelines 
Guidelines comprise recommendations based on evidence. They translate research 
findings (both primary and secondary) into a digestible format for clinicians to 
implement. Ideally they too should be produced using a rigorous and transparent 
process. The shortcomings of contributing evidence are made clear.  The guideline is 
tailored for the local environment and in usable format (paper or electronic).  
Systematic reviews and guidelines are sometimes confused but they both serve 
different purposes. Systematic reviews present a summary of the evidence but do not 
present recommendations. However, the guideline development process includes 
decision making involving judgements around the evidence and the environment in 
which those recommendations are to be used. Such considerations include: 1) a 
balance between benefits and harms, 2) quality of the evidence from systematic 
reviews and other studies, 3) patients' values and preferences, 4) resource utilization, 
5) equity, and 6) feasibility of implementation. The GRADE framework for moving from 
evidence to decisions is helpful in taking these steps 2. 
 
Appropriate dissemination of the guideline is essential for effective uptake and 
implementation of the recommendations; all of which have stemmed from the 
original primary evidence. 
Is this pathway efficient and effective? 
All of the research along this pathway should be fit for purpose and accessible.  
However, there are a number of points where it falls short in quality, resulting in a 
failure to translate research to health benefit and wasting time, effort and money.3,4,5,6  
In 2010, the cost of global life sciences research (mainly biomedical) was  estimated at 
around US$240 billion7  Less than 50% of the published biomedical literature is 
estimated to be adequate in conduct and reporting making more than half of research 
insufficient in quality to be fit for purpose.8,9  This enormous wastage afflicting the 
biomedical research literature has been quantified as 85% of its investment; a 
staggering $200 billion dollars for 2010.  This translates into tens of billions of pounds 
being wasted.9 In dentistry, there is a similar, if not worse problem with poor conduct 
and insufficient reporting of trials.10 
This ideal pathway of translating primary evidence to improved patient care can be 
compared to a system for producing drinking water.  In the same way that a pipeline 
carrying water to a destination can leak water at various points along its journey, the 
quantity of evidence can be depleted at key points (failure to write or publish etc).  
Also, just as distillation of the water improves its quality, research has to be distilled 
through peer review, interpretation and syntheses to become useable clinical 
recommendations. 
What is being done to improve the process of evidence creation? 
Because there are many points of failure along the pipeline, by simply making very 
small adjustments to deal with these at each point, loss of information and 
improvement in the quality evidence can occur with little alteration to the status quo. 
An accumulation of these marginal gains can result in a huge overall improvement in 
the final product of ‘best available evidence’.  This is also known as the 1% 
improvement theory (Figure 3), thought to initiate from Wilhelm Steinitz the first ever 
world chess champion (from 1886 to 1894) who developed modern chess game theory 
on the basis that small advantages accumulate throughout the game to give big 
advantages.  This theory was brought to prominence by the success of the GB 
Olympics cycling team in 2012.11 Over the last 30 years, a number of separate 
collaborations and initiatives have evolved to do just this; improve the evidence flow 
and distillation process by independently reducing losses in evidence quality and 
quantity in a small way to optimize the evidence playing into patient care. 
Clinical Trials; what can be done at the primary research stage? 
Before a trial is even carried out, there is potential for the integrity of the evidence 
flow to be reduced.  Funding for trials should be targeted to where gaps in evidence 
have been identified.  Trials are often carried out with a providence that has more to 
do with happenstance and interest of the researcher than with efficiency and priority 
in mind.  However, this has been changing in many countries with governments, 
research councils and charities (the three main funders of public research) identifying 
areas where evidence is needed and commissioning research for them. This drives 
funding towards need, although some have questioned whether this might stifle 
innovation.   
When the area to be investigated has been identified and the research question 
formulated, the best design has to be chosen to answer that question? This is not a 
matter of simply picking a trial design from a shelf. No two trials are the same and 
there is an acknowledged element of creativity in the research process.12 In the case 
of trials, this is often determined by the environment and requires balance between a 
tightly controlled design, generalisability and practicality at many different levels.13 In 
primary research, there are a number of collaborative efforts to improve trial design, 
conduct and reporting. TRIAL FORGE14 is an initiative to establish a better evidence 
base behind trial design, set up, running and analyses processes. Better understanding 
of what works and what doesn’t will improve currently inefficient mechanisms and 
prevent a cycle of repetition of the same mistakes. Increasing efficiency and 
effectiveness in trials, offers better value for money in clinical research, a growing 
concern in evidence production.14 The role of systematic reviews to identify research 
gaps16 and to use earlier trials to design future trials is well accepted although the 
advice is not well followed.17,18 Attempts to promote this have come through funders 
requiring reviews to justify the request for money and from ethics committees as part 
of the application. The trial should be necessary and designed to succeed in its aims . 
Clinical trials should be registered publically a priori. The World Medical Association’s 
Declaration of Helsinki (Ethical Principles for Medical Research Involving Human 
Subjects) states “Every clinical trial must be registered in a publicly accessible 
database before recruitment of the first subject”.19 There are different clinical trial 
registration sites but one that meets all of the criteria for the International Committee 
of Medical Journal Editors (ICMJE)20 and is free, is Clinical Trials.gov.21 The ICMJE also 
recommends that journals publish the trial registration number at the end of every 
abstract reporting the results of a trial. Unfortunately, it still has not been applied as 
a mandatory requirement for all dental journals to require a priori trial registration 
and some do not even make it a requirement for publication of the article, despite 
having it in their instructions to authors. Journal editors have a significantly important 
role in enforcing trial registration by refusing to publish trial reports that have not 
been registered. Many start to push this requirement by allowing researchers to 
register the trial retrospectively and go on to make it compulsory. The dental research 
community falls far behind our medical colleagues in this respect and it has important 
implications for transparency of trials.22 All Trials is  campaigning for this and provides 
an excellent resource explaining the importance of trial registration and result 
reporting.23   
Once the trial has been carried out (no mean feat in itself but not the focus of this 
paper), there is often a failure to report details in the manuscripts published in 
journals. The length of biomedical manuscripts has historically been limited practically 
by the shortage of physical space available in paper-based journals. A lack of available, 
detailed trial information not only makes it difficult for the readership to appraise the 
quality of the trial and decide whether the results are worth considering, but it can 
also make it difficult for systematic reviewers to extract relevant data. There have 
been two main ways of approaching this. Firstly many journals now offer the option 
of storing information associated with papers digitally, allowing the authors to make 
detailed methodology and datasets available online for readers to access. The second 
way has been a move to push authors towards reporting a minimum set of pre-
specified information in their paper. This minimum information set has been decided 
upon and itemised by CONSORT, the Consolidated Standards of Reporting Trials.24 
Completion of the CONSORT statement checklist is a prerequisite of many journals 
before authors can submit their paper for approval to the journal. 
Using different outcomes and outcome measures also compromises the capacity to 
combine evidence.25 The COMET Initiative, Core outcome Measures in Effectiveness 
Trials26 are a group whose aim is to bring together researchers and stimulate the 
construction of core outcome sets (agreed standard outcomes for trials) to improve 
comparing, contrasting and combining trial results as variability in outcomes and 
outcome measures is one of the main impediments to using primary research in 
systematic reviews. COSMIN, COnsesus-based Standards for the selection of 
Measurement Instruments27 is a linked collaborative effort focused on improving the 
selection of health measurement instruments, ideally to tie in with COMET. 
Mandatory trial registration, COMET, COSMIN and CONSORT aim to reduce poor 
reporting practices including non-reporting or selective reporting of information, 
inconsistent, biased or “spinned” reporting.28,29  When reading the report of a trial in 
a journal, checking the trial protocol on a trial registration website against the report 
makes it is possible to see what was planned to be done, planned to be reported, and 
whether these were adhered to by the researchers. 
Many established standards or guidelines in the field are further collected by the 
EQUATOR Network, Enhancing QUAlity and Transparency Of health Research,30 which 
is a resource aimed at supporting clear, accurate reports for all types of health 
research studies. Here, researchers can also find guidance on statistical analysis and 
handling of missing data etc. At the primary research stage, transparency should also 
be sought concerning potential conflicts of interest both financially and non-
financially (‘academic/professional bias’).31 
Systematic Reviews (the secondary research stage) 
Primary research is assimilated into secondary research, e.g. systematic reviews or 
meta-syntheses. Systematic reviews allow an overview of all the trials on a specific 
topic. The narrative of a systematic review allows us to see how many trials there are, 
what they have looked at, the populations they have investigated and the 
interventions they have studied. It contrasts results of different trials and allows 
identification of sources of heterogeneity. Any such differences in efficacy or 
effectiveness of interventions might guide implementation in different groups, or 
might point towards limited generalizability or different trial conduct.  
If a meta-analysis (a statistical analysis of combined results of trials) is possible, there 
will be a statistical presentation of how the different trials’ findings compare, what 
the relative contribution is of each trial and in the end whether one intervention is 
better than another and in what context. One of the most reputable systematic review 
groups is the Cochrane Collaboration,31 a virtual organization, comprised of many 
different groups, of which the Oral Health Group is one and populated by people from 
different countries and areas of expertise who come together to produce the review. 
Cochrane reviews are known for their thoroughness in review development, they 
insist on publication of a protocol prior to the review being carried out and the result 
is a review that carries weight in its findings as a product of the rigorous process. 
An alternative for registering non-Cochrane reviews is the PROSPERO register.33 A 
priori systematic review protocol registration should be encouraged as it establishes 
which reviews are being carried out as well as reducing the risk that other groups will 
address the same question. It improves rigor through transparency about the 
methodology of the review to be carried out and for updating it. 
PRISMA (Transparent Reporting of Systematic Reviews and Meta-analyses) 
Statement34 has been developed to guide review developers by laying out a minimum 
set of items that should be reported in a review, in a similar way to CONSORT with the 
aim of improving reporting of research at the review stage. Eventually, review findings 
can be evaluated both regarding the direction of any potential recommendation 
towards an intervention, and the strength of evidence underlying that 
recommendation (i.e. the confidence one can have into what was found by the 
review). To do so, the GRADE collaboration have outlined a detailed process (Atkins 
2004), and have recently launched an online tool allowing to bridge the gap between 
secondary research and guideline development.35  
Guideline development stage 
One way of making synthesized evidence usable in practice is to present 
recommendations for best practice in clinical guidelines. The AGREE II (Appraisal of 
guidelines for Research and Evaluation) instrument36 has been developed to evaluate 
the quality of practice guidelines. GRADE35 (previously mentioned) have developed a 
method of assessing evidence quality and linking it to clinical recommendations. More 
specifically, the DECIDE (Developing and Evaluating Communication Strategies to 
Support informed Decisions and Practice Based on Evidence) collaboration37 have 
produced evidence for working out the best dissemination strategies for 
recommendations to promote their use in practice.  
Implementation and outlook 
How can we ensure that these tools to improve clinical research design, conduct and 
reporting and to increase usability of research are employed?  There are a number of 
regulatory opportunities. Funders, who haven’t already, should develop and enforce 
a system where trial design, conduct and reporting complies with standards, is 
transparent and justified.  Journals should require authors to comply with reporting 
standards like CONSORT and PRISMA before manuscripts are even accepted for peer 
review.  Although there is no formal requirement for editors of biomedical journals 
undertake training before taking up an editorship, there are a number of forums that 
offer support, such as International Committee of Medical Journal Editors,38 the World 
Association of Medical Editors,39 the Council of Science Editors,40 and the Committee 
on Publication Ethics.41 
Dissemination of the tools discussed above, needs to be more comprehensive and 
perhaps making them available at a “one-stop shop” and easier to find, would improve 
their uptake. In many, but not all, countries, Ethics Committees already require a priori  
registration of trials. Journals should support this move. Editors and journal peer 
reviewers should require the same for systematic reviews. Journal reviewers also 
should be educated on how to use existing guidelines, as they could act as facilitators 
or even change agents.  Again, there are some resources available to train peer 
reviewers including Critical Appraisal Skills Programme (CASP)42  Making sense of 
evidence, World Association for Medical Editors (WAME)43 Resource for Evaluation of 
Research Articles, Publishing Research Consortium Sense about Science  Peer review: 
the nuts and bolts44 and a programme of training materials for peer reviewers in the 
British Medical Journal.45 
The roles of patients/ participants, clinicians, policy makers and service commissioners 
in improving the quality of evidence is perhaps not as obvious as the roles of 
researchers.  However, patients/ participants and clinicians are well placed to suggest 
priority areas for research, based on experience, both as service users and clinical 
experience.  Policy makers and service commissioners have a strong role to play in 
suggesting priority areas for research based on awareness of gaps in research to 
inform policy creation. 
 
Conclusion 
There are many points along the research process where research is lost and its quality 
is reduced.  The myriad of tools to avoid this are already available and being 
implemented by many.  However, there needs to be more universal usage by all those 
involved in the flow of evidence creation, i.e. those who pay for research (funders), 
produce it (researchers), regulate it (ethics committees), take part in it (patients/ 
participants) and use it (clinicians, policy makers and service commissioners).  
Incorporating these established improvements or standardisations – even though 
they are only small changes at many stages in the evidence flow pathway – will result 
in significant overall improvement in the evidence that we can use at point of care 
with our patients.  We need to reduce research wastage. The water company might 
choose to accept the loss of water from their pipeline as necessary, it being too 
expensive to trace and fix. However, we must take steps to prevent the loss of 
research and research quality along the research pipeline and its associated wastage.  
Also, we owe it to the public whose money has been invested in these trials and whose 
goodwill and trust has been invested in volunteering as participants, on the 
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Figure 1. Evidence Based Practice (EBP) relies on not only the Best Available Evidence 
but also successful incorporation of the clinician’s expertise and each individual 









Figure 2. The flow of evidence creation from trials to guidelines.  Pre-trial research and 








Figure 3. Marginal gains in the flow of evidence. Small improvements are required at 
many stages from the primary research stage, through synthesis of these studies into 
systematic reviews and the incorporation of all of this evidence into guidelines 
preventing loss of integrity and quality in an incremental way. Adapted from “The 
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